Text Size

A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment Rating Scale)

This study has been completed.
Sponsor:
Collaborators:
Eli Lilly and Company
Pudue Pharma
Shire Development LLC
Information provided by:
University of British Columbia
ClinicalTrials.gov Identifier:
NCT00885807
First received: April 20, 2009
Last updated: June 17, 2011
Last verified: June 2011
History of Changes
  Purpose

The purpose of the study is to evaluate the psychometric validation of the Weiss Functional Impairment Rating Scale and the Weiss Symptom Record. It is hypothesized that the Weiss Functional Impairment Rating Scale has strong psychometric properties and good convergent validity with other measures of functioning and discriminant validity from symptoms and quality of life.


Condition
Attention-Deficit/Hyperactivity Disorder

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Psychometric Validation of the Weiss Functional Impairment Rating Scale and the Weiss Symptom Record in Patients With Attention-Deficit Hyperactivity Disorder

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of British Columbia:

Enrollment: 220
Study Start Date: July 2006
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Detailed Description:

The measures for this rating scale were developed at the request of the Canadian Attention Deficit Disorder Resource Alliance to provide clinician friendly tools free of charge as a way of improving screening for ADHD and comorbidity.

Patients are consented during clinic visits and agree to allow use of clinic data for the purpose of this research. They complete additional measure(s) for the purpose of the study. The data is then entered.

Internal consistency will be measured using Cronbach's alpha. Convergent, concurrent and discriminant validity will be measured using Pearson correlations. Domain reliability is determined with factor analysis. Up to 220 patients will be enrolled in the study.

  Eligibility

Ages Eligible for Study:   7 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

People with ADHD from 7 years of age

Criteria

Inclusion Criteria:

  • Compliance to complete the WFIRS is key to inclusion.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00885807

Locations
Canada, British Columbia
Provincial ADHD Program, BC Children's & Women's Health Centre
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Eli Lilly and Company
Pudue Pharma
Shire Development LLC
Investigators
Principal Investigator: Margaret D. Weiss, MD, Ph.D University of British Columbia
Study Director: Chistopher Gibbins, MD BC Children's & Women's Hospital, Vancouver
Study Director: Grant Iverson, MD University of British Columbia
Study Director: Brian Brooks, MD BC Children's & Women's Hospital, Vancouver
Study Director: Li Ying Lu, MD BC Children's & Women's Hospital, Vancouver
  More Information

No publications provided

Responsible Party: Dr. Margaret Weiss, University of British Columbia
ClinicalTrials.gov Identifier: NCT00885807     History of Changes
Other Study ID Numbers: H05-70402
Study First Received: April 20, 2009
Last Updated: June 17, 2011
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
ADHD
WFIRS
WSR

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
 Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on May 19, 2013